GlassScriptPhysician profile
Marnitta L Demming
NPI 1225539984
$6,422.61
in general payments reported to CMS, 2019-2025
18 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $538 · 2022: $1,497 · 2023: $2,481 · 2024: $1,611 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,385 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,385.07 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,430.69 | 2021-2024 | Austedo Xr, Austedo, Uzedy |
| Alkermes, INC. | $835.11 | 2021-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $800.82 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $630.04 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $608.39 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $410.04 | 2022-2025 | Caplyta |
| Lundbeck LLC | $376.91 | 2023-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $292.28 | 2022-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $201.70 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $188.25 | 2021-2022 | |
| Indivior INC. | $178.96 | 2022-2024 | Perseris, Sublocade |
| Axsome Therapeutics, INC. | $134.44 | 2022-2023 | Auvelity |
| Vanda Pharmaceuticals INC. | $97.68 | 2022-2023 | Hetlioz, Fanapt |
| Ironshore Pharmaceuticals INC. | $90.46 | 2023-2024 | Jornay Pm |
| Corium, LLC | $63.80 | 2023 | Azstarys |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioxcel Therapeutics, INC. | $49.10 | 2024 | Igalmi |
| Braeburn INC. | $19.66 | 2025 | Brixadi |
| E.R. Squibb & Sons, L.L.C. | $14.28 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marnitta Demming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.